TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Taysha Gene Therapies, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -2792.3%
- Net margin
- -2728.0%
- Return on equity, FY2025
- -68.5%
Financial strength
- Current ratio
- 17.76
- Debt to equity
- 0.13
- Debt to assets
- 10.5%
- Cash to current liabilities
- 1753.3%
Valuation
- P/E ratio
- –
- Price to sales
- 265.09
- Price to book
- 3.75
- Dividend yield
- –